IDH2 and acute myeloid leukemia: However, Bristol-Myers Squibb recently announced that the Phase III trial evaluating anticancer agent enasidenib (AG-221) for the treatment of IDH2 mutation-positive, relapsed, or refractory acute myeloid leukemia failed to meet the primary endpoint of overall survival.